Current Oncology Reports

, Volume 15, Issue 2, pp 105–112 | Cite as

Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor

  • Hui ZhuEmail author
  • Jorge A. GarciaEmail author
Evolving Therapies (RM Bukowski, Section Editor)


Androgen and the androgen receptor (AR) pathway remain the key targets for emerging new therapies against castration-resistant prostate cancer (CRPC). Adrenal androgens and intratumoral testosterone production appear to be sufficient to activate AR in the castration-resistant setting. This process re-engages AR and allows it to continue to be the primary target responsible for prostate cancer progression. Adrenal androgen production can be blocked by inhibiting cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17), a key enzyme for androgen synthesis in adrenal glands and peripheral tissues. Therapeutic CYP17 inhibition by ketoconazole or by the recently approved adrenal inhibitor abiraterone acetate is the only available choice to target this pathway in CRPC. A new CYP17 inhibitor, with more selective inhibition of 17,20-lyase over 17α-hydroxylase, orteronel (TAK-700), is currently undergoing phase III clinical trials in pre- and postchemotherapy CRPC. In a completed phase II trial in CRPC patients, orteronel demonstrated its efficacy by lowering the levels of circulating androgens, reducing prostate-specific antigen (PSA) levels, and decreasing the levels of circulating tumor cells. Ongoing studies evaluating orteronel in CRPC will further define its safety and role in the management of this disease.


Castration-resistant prostate cancer Orteronel TAK-700 CYP17 inhibitor Hormonal therapy Androgen-deprivation therapy 



H. Zhu: none; J.A. Garcia: consultant to J&J and Astellas and speakers’ bureaus for J&J.


Papers of particular interest, published recently, have been highlighted as • Of importance

  1. 1.
    Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg. 1942;115:1192–200.PubMedCrossRefGoogle Scholar
  2. 2.
    Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.PubMedCrossRefGoogle Scholar
  4. 4.
    • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. This phase III trial demonstrated the overall survival benefit of abiraterone acetate in docetaxel-refractory CRPC patients and led to its FDA approval.PubMedCrossRefGoogle Scholar
  5. 5.
    Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem. 2003;253:89–101.PubMedCrossRefGoogle Scholar
  6. 6.
    Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol. 2000;18:52–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Mohler JL, Gregory CW, Ford 3rd OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Brinkmann AO, Blok LJ, de Ruiter PE, et al. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol. 1999;69:307–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995;16:271–321.PubMedGoogle Scholar
  10. 10.
    Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18:306–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA. 2002;99:11890–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Harper ME, Pike A, Peeling WB, Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol. 1974;60:117–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Koh E, Kanaya J, Namiki M. Adrenal steroids in human prostatic cancer cell lines. Arch Androl. 2001;46:117–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Titus MA, Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11:4653–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10:7121–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004;64:765–71.PubMedCrossRefGoogle Scholar
  18. 18.
    Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–25.PubMedCrossRefGoogle Scholar
  19. 19.
    Suzuki K, Nishiyama T, Hara N, et al. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis. 2007;10:301–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamaoka M, Hara T, Hitaka T, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012;129:115–28.PubMedCrossRefGoogle Scholar
  22. 22.
    O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317–25.PubMedGoogle Scholar
  23. 23.
    Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57:314–9.PubMedGoogle Scholar
  24. 24.
    Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Gregory CW, Johnson Jr RT, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892–8.PubMedGoogle Scholar
  26. 26.
    Palmberg C, Koivisto P, Kakkola L, et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol. 2000;164:1992–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994;54:2861–4.PubMedGoogle Scholar
  28. 28.
    Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999;59:2511–5.PubMedGoogle Scholar
  29. 29.
    Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992;41:665–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95:497–505.PubMedCrossRefGoogle Scholar
  31. 31.
    Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474–8.PubMedGoogle Scholar
  32. 32.
    Hobisch A, Eder IE, Putz T, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998;58:4640–5.PubMedGoogle Scholar
  33. 33.
    Singh RK, Sudhakar A, Lokeshwar BL. Role of chemokines and chemokine receptors in prostate cancer development and progression. J Cancer Sci Ther. 2010;2:89–94.PubMedCrossRefGoogle Scholar
  34. 34.
    Wu JD, Haugk K, Woodke L, et al. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem. 2006;99:392–401.PubMedCrossRefGoogle Scholar
  35. 35.
    Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000;6:703–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404:782–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem. 2000;275:24500–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15:4799–805.PubMedCrossRefGoogle Scholar
  39. 39.
    Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995;147:386–96.PubMedGoogle Scholar
  40. 40.
    • Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol. 2011;29:abstr 4516. This early-phase study demonstrated clinical efficacy of XL184 in metastatic CRPC patients.Google Scholar
  41. 41.
    Ruijter E, van de Kaa C, Miller G, et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999;20:22–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res. 2000;60:944–9.PubMedGoogle Scholar
  43. 43.
    Cher ML, Bova GS, Moore DH, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996;56:3091–102.PubMedGoogle Scholar
  44. 44.
    Palmberg C, Koivisto P, Hyytinen E, et al. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol. 1997;31:216–9.PubMedGoogle Scholar
  45. 45.
    Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res. 1996;2:277–85.PubMedGoogle Scholar
  46. 46.
    Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate. 1998;35:63–70.PubMedCrossRefGoogle Scholar
  48. 48.
    Craft N, Chhor C, Tran C, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999;59:5030–6.PubMedGoogle Scholar
  49. 49.
    Puche C, Jose M, Cabero A, Meseguer A. Expression and enzymatic activity of the P450c17 gene in human adipose tissue. Eur J Endocrinol. 2002;146:223–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Attard G, Reid AH, Olmos D, de Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 2009;69:4937–40.PubMedCrossRefGoogle Scholar
  51. 51.
    Arth GE, Patchett AA, Jefopoulus T, et al. Steroidal androgen biosynthesis inhibitors. J Med Chem. 1971;14:675–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Chart JJ, Sheppard H. Pharmacology and biochemistry of some amphenone analogues and other adrenal cortical inhibitors. J Med Pharm Chem. 1959;1:407–41.PubMedCrossRefGoogle Scholar
  53. 53.
    Gaunt R, Steinetz BG, Chart JJ. Pharmacologic alteration of steroid hormone functions. Clin Pharmacol Ther. 1968;9:657–81.PubMedGoogle Scholar
  54. 54.
    DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981;19:1073–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. Lancet. 1984;2:433–5.PubMedCrossRefGoogle Scholar
  56. 56.
    De Coster R, Caers I, Coene MC, et al. Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol (Oxf). 1986;24:657–64.CrossRefGoogle Scholar
  57. 57.
    Mahler C, Verhelst J, Denis L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer. 1993;71:1068–73.PubMedCrossRefGoogle Scholar
  58. 58.
    Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997;157:1204–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997;80:1755–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025–33.PubMedCrossRefGoogle Scholar
  61. 61.
    Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489–95.PubMedCrossRefGoogle Scholar
  62. 62.
    Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96:1241–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28:1496–501.PubMedCrossRefGoogle Scholar
  65. 65.
    Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res. 2010;16:4319–24.PubMedCrossRefGoogle Scholar
  66. 66.
    Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacodynamics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study. J Clin Oncol. 2010;28:abstr 3084.Google Scholar
  67. 67.
    • Agus DB, Stadler WM, Shevrin DH, et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. J Clin Oncol. 2011;29:abstr 4531. This early-phase study demonstrated clinical efficacy and safety of orteronel in metastatic CRPC patients.Google Scholar
  68. 68.
    Vasaitis T, Belosay A, Schayowitz A, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther. 2008;7:2348–57.PubMedCrossRefGoogle Scholar
  69. 69.
    Kaku T, Hitaka T, Ojida A, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem. 2011;19:6383–99.PubMedCrossRefGoogle Scholar
  70. 70.
    Rowlands MG, Barrie SE, Chan F, et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem. 1995;38:4191–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.PubMedCrossRefGoogle Scholar
  72. 72.
    Haidar S, Ehmer PB, Barassin S, et al. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol. 2003;84:555–62.PubMedCrossRefGoogle Scholar
  73. 73.
    Salem M, Garcia JA. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Curr Oncol Rep. 2011;13:92–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Galsky MD, Small AC, Tsao CK, Oh WK. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin. 2012;62:299–308.PubMedCrossRefGoogle Scholar
  75. 75.
    Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.PubMedCrossRefGoogle Scholar
  76. 76.
    • Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–46. This early-phase study demonstrated clinical efficacy and safety of MDV3100 in metastatic CRPC patients.PubMedCrossRefGoogle Scholar
  77. 77.
    • Scher H, Fizari K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol. 2012;30 Suppl 5:LBA1. This phase III trial demonstrated the overall survival benefit of MDV3100 in docetaxel-refractory CRPC patients.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Solid Tumor OncologyCleveland Clinic Taussig Cancer InstituteClevelandUSA
  2. 2.Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer InstituteGlickman Urologic and Kidney InstituteClevelandUSA

Personalised recommendations